Delcath Systems Stock Earnings Reports

Delcath reported a strong Q1 2026 with operational momentum and updated guidance. Key commercial highlights: 4 center activations in the quarter, record new patient starts (≈0.7 new patients per site per month), 29 REMS‑certified U.S. sites with active discussions at over 50 potential centers, and near completion of U.S. commercial expansion into 9 regions. Management trimmed its year‑end activated center target to 37 (with 40 active centers expected by Q1 2027) but expects higher patient volumes and referral development (boosted by CHOPIN data) to offset slower activations. Financials: Q1 revenue $25.0M (HEPZATO kits $23.3M; CHEMOSAT $1.7M), gross margin 85%, net loss $1.1M, adjusted EBITDA $3.4M, cash and investments $89.3M, zero debt. Company repurchased ~300,000 shares (~$3M) in Q1 under a $25M buyback program ($9M spent to date). Guidance: management reiterates confidence in at least $100M total revenue for 2026 (implying ~20% HEPZATO kit volume growth vs. 2025), expects 85–87% gross margins and positive adjusted EBITDA for the remainder of the year. Clinical pipeline: mCRC trial has 13 activated screening sites (7 patients enrolled; interim results expected late 2027) and mBC trial 4 active sites (targeting ~15 sites by late 2026); company is exploring additional tumor types and CHOPIN‑like combination regimens. Risks and cadence notes: seasonality and site staffing (single trained teams) can create variability; R&D and SG&A spend will increase in 2026 (R&D up materially vs. 2025 but now expected ~70–75% increase rather than 90%; SG&A up ~60%). Europe remains secondary in near term due to reimbursement constraints but useful for investigator‑initiated data generation.